Analysts take a look at Cara Therapeutics, Inc. (NASDAQ:CARA) having this to say.

July 11, 2018 - By Elena Maslow

Cara Therapeutics, Inc. (NASDAQ:CARA) LogoInvestors sentiment decreased to 0.83 in 2018 Q1. Its down 0.10, from 0.93 in 2017Q4. It fall, as 13 investors sold Cara Therapeutics, Inc. shares while 27 reduced holdings. 15 funds opened positions while 18 raised stakes. 15.62 million shares or 1.17% less from 15.80 million shares in 2017Q4 were reported.
Goldman Sachs Gru Inc stated it has 0% of its portfolio in Cara Therapeutics, Inc. (NASDAQ:CARA). Voya Management Limited Liability Company reported 0% stake. Bnp Paribas Arbitrage Sa has invested 0% of its portfolio in Cara Therapeutics, Inc. (NASDAQ:CARA). Aqr Mgmt Ltd Liability Com accumulated 16,817 shares. Franklin Resources stated it has 450,500 shares. Great West Life Assurance Can holds 0% or 2,700 shares in its portfolio. Northern Trust Corporation has 0% invested in Cara Therapeutics, Inc. (NASDAQ:CARA). Shanda Asset Mngmt invested in 0.11% or 54,984 shares. Perigon Wealth Mgmt Llc has 0% invested in Cara Therapeutics, Inc. (NASDAQ:CARA) for 60 shares. Royal State Bank Of Canada reported 4,089 shares or 0% of all its holdings. Ameritas Investment Partners Inc invested in 2,345 shares. 40,054 are owned by Deutsche Fincl Bank Ag. Credit Suisse Ag holds 0% or 30,408 shares. Morgan Stanley reported 0% of its portfolio in Cara Therapeutics, Inc. (NASDAQ:CARA). Bank Of America De holds 23,967 shares.

Since January 24, 2018, it had 0 buys, and 7 selling transactions for $778,740 activity. $81,000 worth of Cara Therapeutics, Inc. (NASDAQ:CARA) was sold by CHALMERS DEREK T.

Cara Therapeutics, Inc. (NASDAQ:CARA) Ratings Coverage

Among 5 analysts covering Cara Therapeutics (NASDAQ:CARA), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Cara Therapeutics had 9 analyst reports since January 19, 2018 according to SRatingsIntel. The rating was upgraded by Janney Capital on Monday, February 12 to “Buy”. On Thursday, March 15 the stock rating was maintained by Canaccord Genuity with “Buy”. The stock has “Buy” rating by H.C. Wainwright on Monday, March 12. On Thursday, May 24 the stock rating was maintained by Laidlaw with “Buy”. H.C. Wainwright maintained the stock with “Buy” rating in Monday, March 19 report. The stock of Cara Therapeutics, Inc. (NASDAQ:CARA) has “Buy” rating given on Friday, May 11 by H.C. Wainwright. The rating was maintained by Canaccord Genuity on Friday, June 29 with “Buy”. The company was maintained on Wednesday, May 23 by H.C. Wainwright. Below is a list of Cara Therapeutics, Inc. (NASDAQ:CARA) latest ratings and price target changes.

29/06/2018 Broker: Canaccord Genuity Old Rating: Buy New Rating: Buy Old Target: $21 New Target: $22 Maintain
24/05/2018 Broker: Laidlaw Rating: Buy New Target: $26.0000 Maintain
23/05/2018 Broker: H.C. Wainwright Rating: Buy New Target: $24.0000 Maintain
11/05/2018 Broker: H.C. Wainwright Rating: Buy New Target: $22.0000 Maintain
19/03/2018 Broker: H.C. Wainwright Rating: Buy New Target: $22.0 Maintain
15/03/2018 Broker: Canaccord Genuity Rating: Buy New Target: $22.0 Maintain
12/03/2018 Broker: H.C. Wainwright Rating: Buy New Target: $22 Reinitiate
12/02/2018 Broker: Janney Capital Old Rating: Neutral New Rating: Buy Old Target: $21 Upgrade
19/01/2018 Broker: Seaport Global Rating: Buy New Target: $27 Initiates Coverage On

The stock increased 4.25% or $0.88 during the last trading session, reaching $21.6. About 812,636 shares traded. Cara Therapeutics, Inc. (NASDAQ:CARA) has risen 1.86% since July 11, 2017 and is uptrending. It has underperformed by 10.71% the S&P500.

Cara Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors in the United States. The company has market cap of $706.32 million. It is developing product candidates that target the body's peripheral nervous system. It currently has negative earnings. The companyÂ’s lead product candidate comprises I.V.

More notable recent Cara Therapeutics, Inc. (NASDAQ:CARA) news were published by: which released: “Cara Therapeutics: Scratching An Itch Left Unscratched” on June 27, 2018, also with their article: “Cara Therapeutics (CARA) Announces Dosing of Patients in Phase 2 Trial of Oral KORSUVA for Pruritus in Stage III-V …” published on July 11, 2018, published: “Is Cara Therapeutics, Inc. a Buy?” on July 01, 2018. More interesting news about Cara Therapeutics, Inc. (NASDAQ:CARA) were released by: and their article: “Merck Has The Best Anti-Cancer Portfolio – Cramer’s Lightning Round (7/6/18)” published on July 09, 2018 as well as‘s news article titled: “Cara Therapeutics: Worth Keeping An Eye On” with publication date: June 28, 2018.

Cara Therapeutics, Inc. (NASDAQ:CARA) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.